Astellas Pharma Inc announced dosing of the first patient in the SKYLIGHT 1 phase 3 pivotal trial for fezolinetant, an investigational oral, non─hormonal compound being studied for the treatment of moderate─to─severe vasomotor symptoms
Ook interessant voor je
